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Abstract
Background/Aim. Antibiotics are the most frequently
used medications in Serbian hospitalized patients. Informa-
tion about antibiotic utilization and sensitivity among inpa-
tients in Serbia is scanty, and there are no available publica-
tions on the topic. The aim of this study was to investigate
the correlation between antibiotic use and bacterial resis-
tance in the Clinical Center Niš, one of the biggest hospitals
in Serbia. Methods.  The data on antibiotics use in inpa-
tients were obtained from the database of the Department
of Pharmacotherapy and expressed as defined daily doses
per 100 bed-days (DBD), during 2003–2007. Bacterial re-
sistances were given as percentages of resistant isolates. Re-
sults. During the investigation period, the overall con-
sumption of antibiotics had a significant decrease in 2007,
by 22.99% (62.23 : 47.92 DBD; p < 0.05). The most fre-
quently used antibiotics were cephalosporins, followed by
penicillins, aminoglycosides and quinolones. Hospital ami-
noglycosides consumption was reduced in 2007 to 59.9%
(13.4 : 5.53 DBD) while the resistance to amikacin was re-
duced from 40.88% to 32.1%. However, utilization of cip-
rofloxacin had a significant increase in 2007 (120.7%).
There was an alarming increase in the level of resistance to
ciprofloxacin in our hospital (from 13.5% to 28.3 % in Es-
cherichia coli and from 11.1 to 30.09% in Proteus mirabilis). Re-
duction of E  coli resistant to amoxicillin+clavulanic acid
correlated significantly with their utilization, while the re-
sistance for all isolates decreased from 52.16% to 24.40%.
Conclusions. These results confirm an association between
the use of antibiotics and the prevalence of resistance. This
methodology could provide good quality indicators of ra-
tional drug use and serve for local monitoring of antibiotics
use and resistance, as well as for external comparison.
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Apstrakt
Antibiotici su najčešći među svim lekovima koji se primenjuju
za lečenje hospitalizovanih bolesnika u Srbiji. Podaci o koriš-
ćenju i osetljivosti na antibiotike kod tih bolesnika oskudni su i
nema dostupnih radova o tome u našoj zemlji. Cilj ove studije
bio je utvrđivanje korelacije između upotrebe antibiotika i ba-
kterijske rezistencije kod bolesnika hospitalizovanih u Klinič-
kom centru Niš (KCN) u periodu od 2003 – 2007. Metode.
Praćenje i analiza upotrebe antibiotika obavljena je u Službi za
farmakoterapiju KCN. Korišćenjem  Anatomical Therapeutic
Chemical/Defined Daily Dose metodologije ukupna potrošnja
antibiotika izražavana je brojem definisanih dnevnih doza na
100 bolesničkih dana (DBD). Ispitivanje i praćenje osetljivosti
bakterija vršeno je u Institutu za zaštitu zdravlja u Nišu. Bakte-
rijska rezistencija izražavana je procentom rezistentnih sojeva
bakterija. Rezultati. U toku petogodišnjeg perioda praćenja,
ukupna upotreba antibiotika redukovana je za 22,99% (62,23 u
2003 : 47,92 DBD u 2007; p < 0,05). Najčešće propisivani an-
tibiotici bili su cefalosporini, aminoglikozidi, penicilini i hino-
loni. Upotreba aminoglikozida smanjena je za 59,9%, dok je
bakterijska rezistencija smanjena sa 40,1% na 32,1%. Utvrđe-
no je značajno povećanje upotrebe ciprofloksacina u 2007. u
odnosu na 2004 (120,7%), što je dovelo do signifikantnog po-
rasta rezistencije (Escherichia coli od 11,1% do 30,09% i Proteus
mirabilis od 15,63% do 28,3%). Nasuprot tome, utvrđeno je da
sniženje rezistencije E.coli signifikantno korelira sa potrošnjom
koamoksiklava, koja je snižena sa 5,09 DBD na 1,19 DBD
(ukupna rezistencija svih izolata snižena je sa 52,16% na
24,40%). Zaključak. Potvrđena je povezanost između upot-
rebe antibiotika i prevalencije bakterijske rezistencije. Prime-
njena metodologija može poslužiti za praćenje pravilnog kori-
šćenja antibiotika i rezistencije na njih, kako u lokalnim okvi-
rima, tako i za komparaciju sa drugim centrima.
Ključne reči:
antibiotici; lekovi, korišćenje; lekovi, rezistencija
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Introduction
Antibiotics are the most frequently used medications in
hospitalized patients (15–30% of all prescribed drugs). It has
been estimated that 30–50% of hospitalized patients receive
antimicrobial agents, and that up to 50% of prescribed anti-
microbial agents are not prescribed optimally 
1–3. It has been
shown that inappropriate antibiotic use significantly contrib-
utes to increasing rates of resistant pathogens 
4, 5. Bacteral re-
sistance is now being recognized as a major factor deter-
mining morbidity, mortality and costs in the hospital. It has
been generally recognized that the prevalence of bacterial re-
sistance among bacteria is an unavoidable consequence of
antibiotics use and that it correlates with the overall use of
antimicrobial drugs 
2, 5. Several lines of evidence suggest that
there is a causal association between the use of antimicrobial
agents and the prevalence of drug resistance in microorgan-
isms 
6–8. Taking into account this escalation in bacterial re-
sistance and the large body of evidence considering the
overuse of antibiotics a rational approach is a strict control of
antibiotic use. Factors that promote the emergence of resis-
tance include frequent use of broad-spectrum antimicrobial
agents, prolonged use of antimicrobial agents, more frequent
use of invasive devices and procedures 
9,10. However, there
are reasons for optimism, as studies in various centers show
rapid reversal of resistance 
7, 8. The 1998 European Confer-
ence entitled “The Microbial Threat” emphasized the im-
portance of collecting and comparing data of antibiotic use
and bacterial resistance from different countries 
11, 12. Infor-
mation about antibiotic utilization and sensitivity among in-
patients in Serbia is scanty, and there are no available publi-
cations on the topic. The purpose of this study was to inves-
tigate the extent of antimicrobial usage and to evaluate the
bacterial resistance in the Clinical Center Niš, one of the
biggest hospitals in Serbia. This study generally used the
World Health Organization (WHO) Anatiomical Therapeutic
Chemical (ATC) Classification System  and the volume unit
– Defined Daily Doses (DDD) 
13, 14.
Methods
In this survey antibiotic consumption and bacterial sus-
ceptibility were monitored in the period 2003-2007. The re-
sults were analyzed in the Clinical Center Niš, a 1460- bed,
3rd tertiary health care university hospital in Serbia, that
comprises departments covering all major specialties except
for infectious diseases, kidney transplantation, hematology,
oncology, surgery and tuberculosis. The study period ex-
tended from 2003 – 2007. In 2003 – 2005, the Clinical Cen-
ter had 417 357, 452 993 bed-days per year.
As this study did not collect any data on individual pa-
tients and surveillance was a part of quality assurance, an
approval by Ethical Committee was not considered neces-
sary.
Utilization of antibiotics in Clinical Center Niš in the
period followed was obtained from the computerized data-
base of the Department of Pharmacotherapy and expressed as
DDD per 100 bed/days (DBD). Defined Daily Doses of anti-
bacterial agents for systemic use listed in the ATC Index
with DDD in the period from 2003 to 2007 were used.
Thirty-five different antibiotic drugs were used in our hospi-
tal.
Until April 2005, there was no antibiotic restriction
policy in the hospital and every physician could prescribe
any antibiotic, so misuse or overuse of antibiotics was com-
mon. There has been the Pharmacotherapy Department here
since 2005. Routine monitoring of the use of antibiotic drugs
and antibacterial resistance was started in the Clinical Center
Niš in 2005 with the aim to prevent an increase in bacterial
resistance and the costs of treatment. Following implementa-
tion of restriction policy in 2005, prescription of aminogly-
cosides, third- and fourth-generation cephalosporins, carbap-
enems, piperacillintazobactam and vancomycyn were placed
under the control of the clinical pharmacologist. These
agents may only be prescribed after consultation with the
clinical pharmacologist or following an approval by the
medical director. Some surgical departments have their own
guidelines for surgical prophylaxis, which were developed in
collaboration with a microbiologist and a clinical pharma-
cologist. Occasional lectures on rational antimicrobial drug
use are given in some departments.
The hospital has three clinical pharmacologists survey-
ing and analyzing drug utilization and bacterial resistance,
while one of them is a president of the Drug and Therapeu-
tics Committee (DTC), within the hospital.
The bacteriological laboratory of the Institute for Public
Health Niš routinely screens bacterial resistance/sensitivity
for all patients requiring antibiotic therapy except for pro-
phylactic use. Bacterial strains were isolated from the clini-
cal material of the hospitalized patients and susceptibility to
antibiotics was assessed by the disc diffusion method.
The process of testing the susceptibility of bacteria to
antibacterial  medicines and the creation of antibiogram are
conducted according to recommendations of the American
National Committee for Clinical and Laboratory Stan-
dards 
14, 15 and according to  the recommendation of the
European Committee for Antimicrobial Susceptibility Test-
ing (EUCAST) and the European Association of Clinical
Microbiology and Infectious Diseases (ESCMID). For the
interpretation of the zones of inhibition the standards were
used. Strains were classified as susceptible or resistant (in-
termediate zones of inhibition were considered resistant).
Bacterial resistances were given as percentages of resistant
isolates. The hospital specialist in infectious diseases and the
clinical pharmacologist analyzed the data provided by the
microbiology unit and based on that created a hospital pro-
file.
The number of the assays performed by the bacterio-
logical laboratory was comparable for the years 2003 (2865),
2004 (2968), 2005 (3120), 2006 (2671) and 2007 (3534).
The burden of resistance for each antibiotic was calculated as
percentage of all resistance + intermediate among all tested
isolates from all patients samples (blood, urine, sputum, etc).
For testing the significance of resistance development
and changes in antibiotics utilization a linear analysis was
used. The Chi-square test was used to compare antibiotic useVolumen 66, Broj 4 VOJNOSANITETSKI PREGLED Strana 309
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in different time periods. Pearson's correlation was used to
determine the relationship between the use of antibiotics and
the bacterial resistance. A statistical significance was accepted
at the 5% level. The WHONET software developed by  the
WHO was utilized for data management 
16. The antibiotic re-
sistance data were obtained and presented with the DBD seg-
ment in tables and figures. The data were visualized as a dia-
gram combining drug utilization (DBD) and resistance.
Results
The consumption of antibiotics in our hospital is shown
in Table 1. During the investigation period a total consump-
tion of antibiotics had a significant decrease (p < 0.01) from
62.23 DBD in 2003 to 47.92 DBD in 2007.
The most frequently used antibiotics were cephalospo-
rins, followed by penicillins, aminoglycosides and quinolones.
In 2003, ceftriaxone was the most frequently prescribed anti-
biotic and made up a quarter of the use (Figure 1).
Escherichia coli was a most frequently isolated bacte-
ria (15.71–19.19%), followed by Staphylococcus aureus,
Staphylococcus epidermidis, Pseudomonas aeruginosa and
other  gram-negative bacilli. The types and frequency of
isolated bacterial strains per each year of the followed pe-
riod are described in Table 2. The rates of resistance of
frequently isolated bacteria in our hospital are presented in
Table 3.
Hospital aminoglycosides consumption significantly
reduced from 2005 (13.4 DBD) to 2007 (5.53 DBD) (59.9%;
p <  0.001) (Figure 1). Resistance to gentamycin and ami-
kacin in our study was relatively high, but it significantly de-
creased during the monitored period. The E. coli resistance
to amikacin reduced from 40.2% to 19.7% (Table 3).
Reduction of E. coli resistant to amoxicil-
lin+clavulanic acid correlated significantly with their utili-
zation (r = 0,944,  p <  0.05), while the resistance for all
isolates was reduced from 61.58% to 46.36%. The depend-
ence of the reduction of E. coli resistance to amoxicil-
lin+clavulanic on their utilization in Clinical Center Niš is
shown in Figure 2. A significant correlation was found
(r =  0.924; p < 0.05).
During the same period, there was a substantial de-
crease in the use of ceftriaxone, while the resistance for all
isolates was reduced from 58.2% to 48.86%.
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*Hospital aminoglycosides consumption was significantly reduced from 2003 to 2007 (p < 0.001).
Fig. 1 – Trends in antibiotic consumption in defined daily doses per 100 bed-days (DBD)
in the Clinical Center Niš  from 2003 to 2007
Table 1
Antibiotic consumption in the Clinical Center Niš from 2003 to 2007
DBD (%)
Antibiotics
  2003 2005  2007
 Ceftriaxone 8.18 (13.14) 3.60 (6.87) 6.09 (12.7)
 Gentamicin 7.42 (11.92) 4.21 (8.04) 3.33 (6.95)
 Bipenicillins 5.94 (9.55) 2.40 (4.58) 1.63 (3.40)
 Ciprofloxacin 2.12 (3.41) 4.68 (10.84) 5.30 (11.06)
 Amikacin 5.47 (8.79) 2.21 (4.22) 2.20 (4.59)
 Coamoxiclav 5.09 (8.18) 2.80 (5.35) 1.19 (2.48)
 Cefotaxime 4.94 (7.94) 1.65 (3.15) 1.28 (2.67)
 Cotrimoxazole 4.26 (6.85) 2.26 (4.32) 1.87 (3.96)
 Ampicillin 3.69 (5.93) 4.79 (9.14) 1.57 (3.28)
 Cefuroxime 0.96 (1.54) 3.82 (7.29) 5.97 (12.40)
 Other 14.16 (22.75) 18.96 (36.90) 13.76 (28.71)
 Total 62.23 (100) 51.38 (100) 47.92* (100)
*Consumption of antibiotics had a significant decrease from 2003 to 2007 (p < 0.01)
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Table 2
Types and frequency of appearance of bacterial strains in the Clinical Center Niš
from 2005 to 2007
Number of bacterial strains (%)
Bacterials strains
 2003  2005  2007
 Echerichia coli 490 (15.71) 500 (18.70) 678 (19.19)
 Staphylococcus aureus 450 (14.42) 370 (13.85) 264 (7.47)
 Staphylococcus epid. 410 (13.14) 236 (8.84) 241 (6.82)
 Enterococcus 290 (9.29) 142 (5.32) 342 (9.68)
 Proteus mirabilis       210 (6.73) 154 (5.77) 177 (5.01)
 Pseudomonas  aeuriginosa 200 (6.41) 198 (7.41) 304 (8.80)
Klepsiella 160 (5.13) 118 (4.42) 201 (7.11)
Eneterobacter 215 (6.78) 146 (5.46) 142 (4.08)
Citrobacter 132 (4.23) 132 (4.94) 138 (3.91)
Acinetobacter 120 (3.85) 83 (3.11) 106 (3.74)
 Other 443 (14.19) 592 (22.16) 941 (26.62)
 Total 3120 (100) 2671 (100) 3534 (100)
Table 3
Resistance of bacterial strains isolated in inpatients in the Clinical Center Niš in 2003 and 2007
Resistant bacterial  strains (%)
E.coli Klebsiella sp. P.  aeuriginosa Eneterobacter sp. Acinetobacter sp. P.  mirabilis
Antibiotics 2003 2007 2003 2007 2003 2007 2003 2007 2003 2007 2003 2007
Ampicillin 73.08 57.61 – – –––– – – 7 7 . 2 7 5 1 . 4 7
Amoxicillin+ cla-
vulanic acid
52.16 24.40 80.00 73.47 83.33 – 81.18 79.22 – 78.86 42.74 28.57
Cefuroxime 27.50 23.88 – 69.74 80.00 – 73.20 64.93 – – 38.67 27.56
Cefotaxime 26.46 22.42 66.67 77.62 – 76.19 68.21 69.57 85.71 90.48 18.99 24.19
Ceftriaxone 29.14 46.08 – 75.59 85.46 91.50 61.21 62.71 87.84 92.80 31.34 26.32
Imipenem 2.50 1.92 0 6.98 8.97 9.77 8.57 – 3.95 12.71 12.50 10.53
Meropenem 3.70 3.7 0 1.66 15.72 11.37 0 2.7 4.41 13.22 0 5.26
Gentamicin 30.34 20.10 71.13 57.14 75.97 53.49 70.23 50.64 83.12 80.30 35.04 27.68
Amikacin 40.20 19.74 58.94 39.56 54.32 43.19 53.10 28.7 78.38 70.42 17.60 14.46
Ciprofloxacin 15.63 28.33 40.00 69.74 44.20 58.64 40.52 52.94 75.32 77.48 11.01 30.09
Number of isolates 490 678 160 201 200 304 215 142 120 106 210 177
DDD – defined daily doses
Fig. 2 – Correlation between the consumption of amoxicillin+clavulanic acid
and the resistance to E. coli
There was an alarming increase in the level of resistance to
ciprofloxacin in our hospital (from 13.5% to 28.3% to E. coli
and from 11,1 to 30.09% to P. mirabilis). The dependence of the
development of E. coli resistance to ciprofloxacin on their utili-
zation in the Clinical center Niš is shown in Figure 3. A signifi-
cant correlation was found (r =  0.827, p = 0,025).Volumen 66, Broj 4 VOJNOSANITETSKI PREGLED Strana 311
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S. aureus resistant to vancomycin and the vancomycin-
resistant enterococcus were not detected.
DDD – defined daily doses
Fig. 3 – Correlation between the consumption of
ciprofloxacin and the resistance to E. coli
Discussion
Utilization of antibiotics in Serbia is among the highest
in Europe, mostly due to overuse of cephalosporines and
aminoglycosides. The European Surveillance of Antibiotic
Consumption (ESAC) found large differences in antibiotic
use in inpatients. Utilization of antibiotics in the world varied
greatly, from the extremely high in Croatia and Greece, next
rate in France and to the lowest one was in the Netherland. In
this study we found high antibiotic utilization and high re-
sistance rates in our hospital compared with other coun-
tries 
1, 11, 12, 18. A survey carried out at three university hospi-
tals, in another country, showed lower total antibiotic con-
sumption to that found at our hospital 
l6, 19. Unfortunately, no
resistance data were included in these studies.
We found high rate of resistance among the most com-
monly used antibiotics (aminoglycosides, cephalosporines,
fluoroquinolones) 
20. Here it was found that resistance of P.
aeruginosa to gentamicin, was changed from 75.9% of re-
sistant strains in 2005, to 53.5% in 2007. This means that for
P. aeruginosa infections change led to improved sensitivity,
though it is clear that gentamicin cannot be used for this kind
of infection 
1, 17. Goryachkina et al. 
11 showed the decreased
resistance level for gentamicin (80% to 40%) in Russia from
2003–2005.
At the same time, we showed a decreased resistance
level for amoxicillin+clavulanic acid (61.58 to 46.36%; same
strains were tested). This provides an overall impression on
coincidence of resistance and antibiotic overuse. The resis-
tance of E. coli was decreased significantly from 52.16% of
resistant strains in 2005, to 24.40% in 2007.
At the beginning of this study, utilization of ciprofloxacin
was low in our hospital (2.12 DBD). The resistance of E.coli
in inpatients was at a level of 15.5%. In the study period cipro-
floxacin utilization increased significantly (p < 0.001). Bacte-
rial resistance followed this trend very closely and reached
28.3% in 2007. This is a result of the increased consumption
of ciprofloxacin from 2005 2007, the single most prescribed
drug. Now, the increased levels of resistance to fluoro-
quinolones among nosocomial isolates like P. aeuriginosa,
Serratia sppecies and Klebsiella sppecies have been reported
worldwide.
The influence of hospital antibiotic policy is responsible
for this delay. Ciprofloxacin was not placed on restricted an-
tibiotics list in the same period in our hospital. Fluoro-
quinolone resistance to E.coli is emerging as a significant
problem in hospitals. Urbanek et al. 
5 have shown a correla-
tion between the increased use of fluoroquinolones and the
increase in E.coli resistance. Results of numerous studies
show the impact of fluoroquinolone utilization on bacterial
resistance and support the need for controlled use of these ef-
fective antibiotics 
5, 19, 21. Periods of extensive ciprofloxacin
use were associated with a significant increases in resistance.
Similarly to our results, the resistance of E.coli  to ciproflox-
acin in Spain was increased from 13.8% in 2001, to 23.4% in
2005 
10–12. A total ciprofloxacin use was an independent pre-
dictor of the burden of ciprofloxacin resistance in E. coli in
hospitals 
21–23. Our data support the concept that a written
antibiotic policy which balances the use of various antibiotic
classes may help to avoid disturbances of a hospital′s micro-
bial sensitivity patterns 
21–25. As antibacterial resistance is a
multifactorial problem, a multisectoral effort is needed to
control it. The problem of antibacterial resistance needs to be
addressed in a continuous proccess of actions. The key areas
of community recommendations for the control of bacterial
resistance are surveillance of antibiotic consumption and re-
sistance rates, optimizing antibiotic use, education, preven-
tion and control 
2, 3, 26, 27.
Conclusion
These results confirm an association between the
prevalence of bacterial resistance and use of antibiotics.
Monitoring of bacterial resistance can serve as an indicator
of quality of antibiotic use. A combined presentation of anti-
biotic utilization and bacterial resistance provides clear indi-
cation on both problems in relation to each other. This meth-
odology seems to be beneficial for external comparisons as
well as local regulation of antibiotics use and resistance.
Programs for the management of bacterial resistance usually
include modifications of antibiotic use, especially in the de-
creased use of ciprofloxacin and the third-generation cepha-
losporins. Physicians training should be an important part of
efforts against antibiotic resistance. National guidelines on
this topic, as well as good diagnostic and therapeutic proto-
cols are important. A rational and strict antibiotic policy is,
thus, of great importance for the optimal use of these agents.
The obtained results are the basis for further analysis of
bacterial resistance in correlation with antibiotic consump-
tion in the Clinical Center Niš in Serbia.Strana 312 VOJNOSANITETSKI PREGLED Volumen 66, Broj  4
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